You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a novel highly effective influenza vaccine

    SBC: FLUGEN INC            Topic: NIAID

    DESCRIPTION provided by applicant Seasonal influenza flu virus an NIAID category C priority pathogen causes widespread infection resulting in at least million cases of severe illness and deaths worldwide Young children and elderly or immunocompromised individuals are typically at greater risk of severe illness or death from influenza Newly emerging strains can result ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. RNA Detection as an Improved Diagnostic Assay for Human Leptospirosis

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION provided by applicant Leptospirosis a zoonotic disease is an important public health problem worldwide It is caused by spirochete bacteria belonging to nine species and more than serovars of the genus Leptospira In the US there is increasing awareness of the importance of leptospirosis as the cause of disease among inner city populations military personnel and individuals ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION provided by applicant This proposal seeks to develop a novel vaccine against Lyme disease by targeting Ixodes scapularis proteins critical for Borrelia burgdorferi transmission from the tick to mammalian host Earlier work has identified four tick proteins Salp TRE tHRF and TSLPI that facilitate different steps of spirochete transmission and immunity against these protein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. STTR Phase I: Hydrogen Bromine Electrolysis for Highly Efficient Hydrogen-Based Energy Storage and High Value Chemical Applications

    SBC: Proton Energy Systems, Inc.            Topic: CT

    The broader impact/commercial potential of this project includes applications ranging from peak load shifting, grid buffering for renewable energy input, frequency regulation, and chemical conversions. As the percentage of energy from renewables on the grid increases, energy storage will be essential to stabilize the supply and demand. Currently, 20-40% of wind energy is often stranded due to the ...

    STTR Phase I 2014 National Science Foundation
  6. STTR Phase I: 24x7 mobile wireless monitoring of patient's vitals to proactively manage disease recovery

    SBC: Argosy Omnimedia, Inc.            Topic: SH

    The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is found in the proposed technology development that facilitates direct, ubiquitous acquisition of key biomedical data, with little or no human intervention or introduction of errors, has the potential to reduce the costs of healthcare and to revolutionize healthcare delivery throughout our so ...

    STTR Phase I 2014 National Science Foundation
  7. STTR Phase I: Ferrofluidic enclosures for enhanced control of thermal and magnetic fields in spin-stabilized atomic micro-devices

    SBC: COMMET LLC            Topic: EW

    The broader impact/commercial potential of this project is determined by new consumer products and new industries which would flourish on portable and reliable atomic clocks, gyroscopes, and magnetometers when they become available. Proposed compact thermal and magnetic enclosure reduces the most bulky part of such devices and provides an avenue for further miniaturization. A chip-scale atomic clo ...

    STTR Phase I 2014 National Science Foundation
  8. Development of VPL Vaccine for RSV

    SBC: SIGMOVIR BIOSYSTEMS, INC.            Topic: NIAID

    Project Summary Human respiratory syncytial virus (RSV) is recognized as the single most important viral cause of acute respiratory disease in infants and young children worldwide. Elderly populations and immunocompromised individuals are also at significant risk for serious RSV disease. Despite this very substantial disease burden imposed by RSV worldwide, there are no vaccines available. Severa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Effect of VBP15, a dissociative steroidal analogue, on intestinal epithelial repair processes in inflammatory bowel disease

    SBC: REVERAGEN BIOPHARMA, INC.            Topic: NIDDK

    ? DESCRIPTION (provided by applicant): Glucocorticoids (e.g. prednisolone) are prescribed frequently to treat inflammatory bowel disease (IBD). Despite effectiveness, adverse side effects believed to be caused by GRE-mediated transcriptional propertieslimit long term use of glucocorticoids in IBD patients. Furthermore, these GRE-mediated transcriptional activities have been previously shown to ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Evaluation of VBP15 a dissociative steroidal analogue on pain and inflammation

    SBC: REVERAGEN BIOPHARMA, INC.            Topic: NIMHD

    DESCRIPTION (provided by applicant): The treatment of pain in Sickle Cell Disease (SCD) is challenging for both patients and providers and is associated with significant disparities in healt care delivery. While the role of ongoing inflammation during vasooclusive crisis and pain is recognized, effective therapeutic interventions are lacking. Glucocorticoids, with their anti-inflammatory propertie ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government